ERBB2 and breast cancer: The ATEMPT 2.0 trial (NCT04893109) is evaluating whether six cycles of T-DM1 followed by trastuzumab can decrease toxicity while maintaining efficacy and will compare toxicities of this regimen to TH in patients with stage I HER2-positive breast cancer.